InMed Pharmaceuticals Inc.
INM
$2.12
-$0.23-9.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.50% | -12.53% | -11.94% | 5.17% | 11.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.50% | -12.53% | -11.94% | 5.17% | 11.18% |
| Cost of Revenue | -7.46% | -2.79% | -7.60% | 20.92% | 27.97% |
| Gross Profit | 55.02% | -27.63% | -18.89% | -17.87% | -21.54% |
| SG&A Expenses | 13.10% | 11.38% | 11.42% | 6.01% | -0.84% |
| Depreciation & Amortization | -3.05% | -1.56% | 1.49% | 5.48% | 8.61% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.01% | 6.02% | 0.93% | -0.13% | 1.74% |
| Operating Income | 2.66% | -21.73% | -11.02% | 3.45% | 2.92% |
| Income Before Tax | -6.44% | -36.71% | -24.55% | 2.27% | 3.35% |
| Income Tax Expenses | -- | 294.44% | 115.15% | 12.70% | -45.80% |
| Earnings from Continuing Operations | -6.34% | -36.79% | -24.60% | 2.26% | 3.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.34% | -36.79% | -24.60% | 2.26% | 3.42% |
| EBIT | 2.66% | -21.73% | -11.02% | 3.45% | 2.92% |
| EBITDA | 2.65% | -22.52% | -11.33% | 3.71% | 3.20% |
| EPS Basic | 64.31% | 49.85% | 57.65% | 70.48% | 76.57% |
| Normalized Basic EPS | 64.29% | 49.89% | 57.67% | 70.49% | 76.54% |
| EPS Diluted | 64.31% | 49.85% | 57.65% | 70.48% | 76.57% |
| Normalized Diluted EPS | 64.29% | 49.89% | 57.67% | 70.49% | 76.54% |
| Average Basic Shares Outstanding | 156.61% | 139.48% | 154.74% | 222.31% | 210.71% |
| Average Diluted Shares Outstanding | 156.61% | 139.48% | 154.74% | 222.31% | 210.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |